These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34209595)

  • 61. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
    Magnuson EA; Vilain K; Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ;
    Am Heart J; 2015 Dec; 170(6):1140-50. PubMed ID: 26678636
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Net Clinical Benefit of Edoxaban for Stroke, Mortality, and Bleeding Risk: Modeling Projections for a European Population.
    Blann AD; Pisters R; Lip GYH
    JACC Clin Electrophysiol; 2016 Feb; 2(1):47-54. PubMed ID: 29766853
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry].
    Renda G; Patti G; Sangiuolo R; Attena E; Malpezzi MG; De Caterina R;
    G Ital Cardiol (Rome); 2016 Nov; 17(11):922-931. PubMed ID: 27996998
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
    J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation.
    Quinn GR; Severdija ON; Chang Y; Singer DE
    Circulation; 2017 Jan; 135(3):208-219. PubMed ID: 27799272
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
    Cohen AT; Ay C; Hainaut P; Décousus H; Hoffmann U; Gaine S; Coppens M; da Silva PM; Castro DJ; Amann-Vesti B; Brüggenjürgen B; Levy P; Bastida JL; Vicaut E; Laeis P; Fronk EM; Zierhut W; Malzer T; Bramlage P; Agnelli G;
    Thromb J; 2018; 16():9. PubMed ID: 29719492
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
    Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Antman EM; Braunwald E; Giugliano RP
    Thromb Haemost; 2021 Feb; 121(2):140-149. PubMed ID: 32920808
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study.
    Russo V; Attena E; Rago A; Melillo E; Di Micco P; Papa AA; Napolitano G; D'Onofrio A; Golino P; Nigro G
    J Clin Med; 2020 May; 9(6):. PubMed ID: 32471222
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study.
    Nielsen PB; Søgaard M; Jensen M; Ording AG; Lip GY
    Int J Stroke; 2022 Jun; 17(5):536-544. PubMed ID: 34142600
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The thromboembolism risk of low-risk atrial fibrillation patients with different clinical characteristics].
    Liu XB; Jia ZX; Xia SJ; He L; Lu SX; Guo XY; Li SN; Liu N; Jiang CX; Sang CH; Tang RB; Long DY; Yu RH; Bai R; Wu JH; Du X; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):735-739. PubMed ID: 32957755
    [No Abstract]   [Full Text] [Related]  

  • 73. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study.
    Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L
    Eur Heart J Qual Care Clin Outcomes; 2024 Jan; 10(1):55-65. PubMed ID: 36941126
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.
    Yamashita T; Koretsune Y; Ishikawa M; Shiosakai K; Kogure S
    J Arrhythm; 2019 Feb; 35(1):121-129. PubMed ID: 30805052
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
    Marston XL; Wang R; Yeh YC; Zimmermann L; Ye X; Gao X; Brüggenjürgen B; Unverdorben M
    Int J Cardiol; 2022 Jan; 346():93-99. PubMed ID: 34780886
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.
    Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
    Sci Rep; 2019 Apr; 9(1):6690. PubMed ID: 31040359
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry.
    Pope MK; Atar D; Svilaas A; Hole T; Nielsen JD; Hintze U; Crisby M; Raatikainen P; Airaksinen KEJ; Virdone S; Pieper K; Kayani G; Le Heuzey JY; Steffel J; Stepinska J; Bassand JP; Camm AJ;
    Ann Med; 2021 Dec; 53(1):485-494. PubMed ID: 33818226
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.
    Zimerman A; Braunwald E; Steffel J; Van Mieghem NM; Palazzolo MG; Murphy SA; Chen CZL; Unverdorben M; Ruff CT; Antman EM; Giugliano RP
    JAMA Cardiol; 2024 Sep; 9(9):817-825. PubMed ID: 38985461
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study].
    Fazio G; Squizzato A; Mazzetti M; Mannarini A; Fischetti A; Colonna P
    G Ital Cardiol (Rome); 2021 Jan; 22(1):70-79. PubMed ID: 33470246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.